tradmap

COAG Earnings Hemab Therapeutics Holdings, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Chart & overview → Latest filing

Quarterly results

Diluted EPS (quarterly)
-$24 -$12 $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$24M -$12M $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-5% 3% 11% 0% Q1 '25 Q2 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–4 of 4
Q2 20262026-06-30-0.802026-08-1110-Q
Q1 20262026-03-31-23.982026-05-2110-Q
Q2 20252025-06-30-12.91——
Q1 20252025-03-31-16.18——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.